Michael J. Ferguson

University of Louisville
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Year:

2026

e23540 Background: Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare, aggressive variant of inflammatory myofibroblastic tumor (IMT) that occurs in children and young adults. The most recent retrospective review documented just over 55 cases in the literature. In the last year, our hospital system has had two EIMS patients present with novel characteristics. Due to the rarity of EIMS, this retrospective analysis was conducted to understand prognostic factors and treatment patterns of EIMS compared with its more benign variant, IMT. Methods: In this single-institution retrospective analysis, patients with IMT and EIMS were identified between 2002-2024 from both our pediatric and adult sarcoma programs. Patient data was extracted from the electronic medical record (EMR). Relevant clinical factors including demographics, molecular testing, treatment, and outcomes were obtained. Results: Seventeen patients were identified at Indiana University Simon Comprehensive Cancer Center and Riley Children’s Hospital with IMT or EIMS. Median age at diagnosis was 8.5 years with a range of 1-24 years. 76% of the patients were White, 11% Black, and 11% Asian. Biological sex ratio was 8M:9F. The most common primary tumor site was bladder (N = 4) and abdominal/peritoneum (N = 4) with others arising in the lung/pleura, liver, mediastinum, trachea, and brain. Most tumors were locally advanced, with three cases of metastasis at the time of diagnosis, both of the EIMS cases and one IMT of the lung. Both patients over the age of 18, one EIMS and one IMT, were metastatic at diagnosis. Molecular analysis was performed on 6 of the cases, all since 2019. One of the EIMS patients had a CLTC-ALK fusion which is more commonly found in IMTs. This patient with the CLTC-ALK fusion progressed on crizotinib therapy but has had a partial response to 2 nd generation ALK inhibitor, alectinib. The other patient with EIMS had recurrence after stopping crizotinib post tumor resection, but has had a sustained complete response with reintroduction of crizotinib. The median OS for the living cohort (N = 16) is 68 mos (range 6-174 mos), and 1 patient with IMT passed away in 2002 with limited documentation prior to EMR being available. Conclusions: EIMS is an aggressive variant of IMT with a paucity of cases reported in the literature. This single institution retrospective review displayed that EIMS was more likely to recur and/or present with metastatic disease compared to IMT, with the first known report of a CLTC-ALK fusion in EIMS which usually harbors RANBP2-ALK fusions. A multi-institutional study will be helpful to understand the full slate of prognostic factors and biology to tailor the best treatment regimen for this biologically distinct sarcoma.

Year:

2025

Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play a role in the pathogenesis of bone cancer. Osteosarcoma may also develop as a direct result of the long-term side effects of radiation therapy. With the implementation of a multimodality approach to treatment, including multiagent neoadjuvant and adjuvant chemotherapy regimens, targeted therapy options, surgery, and radiation, individuals with Ewing sarcoma and osteosarcoma are showing higher cure rates and improved overall survival. The NCCN Guidelines for Bone Cancer provide a consensus and evidence-based framework for the workup, management, and surveillance of local and recurrent/metastatic disease.

Year:

2025

Introduction: Ovarian Sertoli cell tumors represent a subset of sex cord stromal tumors and are exceedingly rare in prepubertal children. Here, we report a girl with vaginal bleeding due to a Sertoli cell tumor who was originally thought to have McCune-Albright syndrome (MAS). Case Presentation: A previously healthy girl presented at age 2 years 6 months with breast development and vaginal bleeding. On exam, she had Tanner 4 breasts, Tanner 1 pubic hair, estrogenized vaginal mucosa, and a café-au-lait macule. Laboratory studies revealed an elevated estradiol with suppressed gonadotropins and negative tumor markers. Her bone age was advanced by more than 3 years. Pelvic ultrasound (US) revealed an enlarged uterus and a slightly larger left compared to right ovary. She was started on tamoxifen for presumed MAS. A repeat pelvic US 1 month later showed a heterogenous mass in the left ovary which was subsequently resected. Pathology revealed a Sertoli cell tumor, lipid-rich variant. Germline sequencing revealed a pathogenic STK11 variant, diagnostic for Peutz-Jeghers syndrome (PJS). Conclusion: The findings in our patient were strikingly similar to those encountered in MAS. To our knowledge, our patient is the youngest ever reported to present with precocious puberty due to a Sertoli cell tumor in the setting of PJS.

Year:

2025

Here we present a case of metastatic PNET which arose from an immature teratoma that was refractory to standard Ewing sarcoma chemotherapy. This PNET was determined to have elevated levels of ALK protein via IHC. The patient was treated with crizotinib on a palliative basis with a sustained response.

Year:

2023

Collaborators (2)

Daniel J. Olson

Assistant Professor of Medicine

University of Chicago

UNITED STATES
View details

Susan M. Hiniker

Stanford University

UNITED STATES
View details